Journal: Journal of Nanobiotechnology

Article Title: Programmable trivalent nanocage vaccine confers durable cross-species protection against Bordetella bronchiseptica infection

doi: 10.1186/s12951-026-04157-z

Figure Lengend Snippet: Cellular immune responses in C57BL/6 mice induced by mi3-F1P2Fim2 immunization. Two weeks after booster immunization, spleens and serum were collected from immunized mice ( n = 5) for assessment of cellular immune responses. ( A ) The number of IFN-γ or IL-4 secreting cells in splenic lymphocytes was measured by ELISpot assay ( n = 5). Representative images from each group are shown. ( B ) Splenic lymphocyte proliferation in response to antigen stimulation was assessed ( n = 5). ( C ) Levels of IL-2, IL-4, and IFN-γ in the culture supernatant of splenic lymphocytes were measured ( n = 5). ( D ) Serum levels of IL-2, IL-4, and IFN-γ were measured two weeks after booster immunization ( n = 5). ( E ) Percentages of CD4⁺ and CD8⁺ T cells among splenic lymphocytes were determined by flow cytometry ( n = 5). Representative images from each group are shown. Data are presented as mean ± SEM. Statistical significance was determined by one-way ANOVA (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant)

Article Snippet: For cytokine ELISA, ELISA kits for mouse IFN-γ, IL-4, and IL-2 (LiankeBio) were used to measure the secretion levels of IFN-γ, IL-4, and IL-2 in the supernatant of antigen-stimulated splenocytes as well as in the serum of mice two weeks after booster immunization.

Techniques: Enzyme-linked Immunospot, Flow Cytometry

Journal: Oncoimmunology

Article Title: Systemic administration of β-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer.

doi: 10.1080/2162402X.2017.1387347

Figure Lengend Snippet: Figure 3. BG34-200 treatment augments systemic activation of T cells recognizing melanoma antigen. (A) Splenocytes or TDLN cells were stimulated with gp10025-33 peptide. IFN-g and IL-2 levels in the culture media were assessed using ELISA. B. Frequencies of CD3, CD4, CD8 T cells and their expression of CD62L and CD44 in spleen and TDLN were determined by FACS analysis. C. TDLN cells were subjected to intracellular cytokine staining for determining the frequency of gp10025-33 -specific T cells. (A) and (B) were graphed as means ± SD. Each data point represents one of three replicates of samples from individual TDLN or spleen. * p < 0.05, ** p < 0.01. Significance was determined using Student’s t test.

Article Snippet: Mouse IFN- and IL-2 ELISA kits were purchased from R&D Systems (Minneapolis, MN).

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Expressing, Staining

Journal: Cell Communication and Signaling : CCS

Article Title: Tumorous IRE1α facilitates CD8 + T cells-dependent anti-tumor immunity and improves immunotherapy efficacy in melanoma

doi: 10.1186/s12964-024-01470-8

Figure Lengend Snippet: Tumorous IRE1α promotes the secretion of Th1-related chemokine and cytokines by activating NF-κB. A , D Immunoblotting analysis of IRE1α, p-IRE1α, p65, p-p65, XBP1s and GAPDH in A2058 cells treated with TG (0.5 µM) or HA15 (10 µM) for 24 h after pretreated with or without STF-083010 (10 µM), MKC8866 (0.5 µM) or IRE1α siRNA for 24 h. B - C , E - H Relative mRNA level ( n = 6) and ELISA ( n = 4) analysis of CXCL9, CXCL10, CXCL11, TNF-α and IL-6 in A2058 cells treated with TG (0.5 µM) or HA15 (10 µM) for 24 h after pretreated with or without STF-083010 (10 µM), MKC8866 (0.5 µM) or BAY 11-7085 (1 µM) for 24 h. I A2058 cells treated with TG (0.5 µM) or HA15 (10 µM) for 24 h after pretreated with or without MKC8866 (0.5 µM) for 24 h were subjected to ChIP with normal mouse IgG, NF-κB or Pol-II antibody as indicated ( n = 3). J A2058 cells treated with TG (0.5 µM) or HA15 (10 µM) for 24 h were subjected to ChIP with normal mouse IgG, XBP1s or Pol-II antibody as indicated ( n = 3). ChIP samples were analyzed by qPCR using primers indicated in Additional file : Table S3. Data are representative of at least three independent experiments and shown as mean ± SD. Two-tailed Student’s t-test or two-way ANOVA (* p < 0.05; ** p < 0.01; *** p < 0.001)

Article Snippet: ELISA analysis on culture medium of melanoma cells or the blood serum of mice after indicated treatment was performed using the Human IL-6 ELISA Kit (Neobioscience, EHC007.96), Human TNF-α ELISA Kit (Neobioscience, EHC103a.96), Human MIG/CXCL9 ELISA Kit (Neobioscience, EHC114.96), Human IP-10/CXCL10 ELISA Kit (Neobioscience, EHC157.96), Human I-TAC/CXCL11 ELISA Kit (Neobioscience, EHC084.96), Mouse TNF-α ELISA Kit (Elabscience, E-MSEL-M0002), Mouse IL-2 ELISA Kit (Elabscience, E-MSEL-M0036), Mouse IL-6 ELISA Kit (Elabscience, E-EL-M0044c), Mouse ELISA Kit MIG/CXCL9 ELISA Kit (Elabscience, E-EL-M3077), Mouse IP-10/CXCL10 ELISA Kit (Elabscience, E-EL-M0021c), Mouse I-TAC/CXCL11 ELISA Kit (Elabscience, E-EL-M0056c) and Mouse HMGB-1 ELISA Kit (Elabscience, E-EL-M0676c) according to the manufacturer’s instructions.

Techniques: Western Blot, Enzyme-linked Immunosorbent Assay, Two Tailed Test